Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis (DIFFEREN-STAD)
A Multi-center, Exploratory Study to Assess Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Sponsor: Regeneron Pharmaceuticals
This PHASE4 trial investigates Dermatitis Atopic and is currently completed. Regeneron Pharmaceuticals leads this study, which shows 11 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Oct 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Sep 2022 — Aug 2023 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Jun 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Oct 2021 — Jun 2022 [monthly]
Recruiting PHASE4
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE4
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE4
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE4
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .